| Symbol | BMRN |
|---|---|
| Name | BIOMARIN PHARMACEUTICAL INC |
| Sector | HEALTH CARE |
| Region | UNDEFINED |
| Industry | Pharmaceutical Preparations |
| Address | 105 DIGITAL DRIVE, NOVATO, CA 94949 |
| Telephone | 4155066700 |
| Fax | — |
| — | |
| Website | https://www.biomarin.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | BioMarins focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarins Roctavian (hemophilia A gene therapy) is poised to potentially launch in the 2022-23 timeframe. Additional info from NASDAQ: |
New Form SCHEDULE 13G - BIOMARIN PHARMACEUTICAL INC <b>Filed:</b> 2026-04-29 <b>AccNo:</b> 0002100119-26-000245 <b>Size:</b> 7 KB
Read more(10% Negative) BIOMARIN PHARMACEUTICAL INC (BMRN) Announces Delay in disease Trials for Pompe disease Due to Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment
Read moreBioMarin to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, May 4, 2026, at 4:30pm ET
Read moreNew Form ARS - BIOMARIN PHARMACEUTICAL INC <b>Filed:</b> 2026-04-21 <b>AccNo:</b> 0001308179-26-000313 <b>Size:</b> 2 MB
Read moreNew Form DEFA14A - BIOMARIN PHARMACEUTICAL INC <b>Filed:</b> 2026-04-21 <b>AccNo:</b> 0001628280-26-026298 <b>Size:</b> 2 MB
Read moreNew Form SCHEDULE 13G/A - BIOMARIN PHARMACEUTICAL INC <b>Filed:</b> 2026-03-26 <b>AccNo:</b> 0000102909-26-000752 <b>Size:</b> 7 KB
Read moreDavis George Eric 🔴 sold 1.3K shares of BIOMARIN PHARMACEUTICAL INC (BMRN) at $56.05 Transaction Date: Mar 18, 2026 | Filing ID: 019862
Read moreGuyer Charles Greg 🔴 sold 1.7K shares of BIOMARIN PHARMACEUTICAL INC (BMRN) at $56.05 Transaction Date: Mar 17, 2026 | Filing ID: 019857
Read moreMueller Brian 🔴 sold 2.1K shares of BIOMARIN PHARMACEUTICAL INC (BMRN) at $56.05 Transaction Date: Mar 17, 2026 | Filing ID: 019853
Read moreDirector Hardy Alexander 🔴 sold 4.3K shares of BIOMARIN PHARMACEUTICAL INC (BMRN) at $56.05 Transaction Date: Mar 17, 2026 | Filing ID: 019847
Read more